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Monoclonal antibodies (MAbs) to the hemagglutinin-neuraminidase (HN) glycoprotein of Newcastle disease
virus delineate seven overlapping antigenic sites which form a continuum on the surface of the molecule.
Antibodies to five of these sites neutralize viral infectivity principally by preventing attachment of the virion to
cellular receptors. Through the identification of single amino acid substitutions in variants which escape
neutralization by MAbs to these five antigenic sites, a neutralization map of HN was constructed, identifying
several residues that contribute to the epitopes recognized by MAbs which block the attachment function of the
molecule. These epitopes are defined, at least in part, by three domains on HN: residues 193 to 201; 345 to 353
(which include the only linear epitope we have identified in HN); and a C-terminal domain composed of residues
494, 513 to 521, and 569. To identify HN residues directly involved in receptor recognition, each of the variants
was tested for its ability to agglutinate periodate-modified chicken erythrocytes. One variant with a single
amino acid substitution at residue 193 was 2.5- to 3-fold more resistant to periodate treatment of erythrocytes
than the wild-type virus, suggesting that this residue influences the binding of virus to a sialic acid-containing
receptor(s) on the cell surface.
The hemagglutinin-neuraminidase (HN) glycoprotein of
Newcastle disease virus (NDV) possesses both the receptor
recognition and neuraminidase (NA) activities associated
with the virus. In virions, HN is found as spikes protruding
from the cellularly derived viral membrane, in which it is
anchored near its amino terminus (33).
The amino acid sequences of the HN glycoproteins of
several NDV isolates have been deduced from the nucleo-
tide sequences of cloned genes (20, 23, 24, 31, 32). There is
extensive amino acid homology between the HN glycopro-
teins of the different isolates, approximately 90% in any
pair-wise comparison (29). Each has a hydrophobic stretch
of amino acids near its amino terminus that is presumed to be
the membrane-spanning domain. Six potential asparagine-
linked glycosylation sites, predominantly in the carboxy-
terminal half of the molecule, are also highly conserved in
the HN of most of the isolates (29).
There is also extensive conservation of the number and
position of cysteine residues among the HN sequences of
different NDV isolates. Twelve of the 13 cysteine residues
carboxy terminal to the proposed membrane-spanning re-
gion are conserved. Only the cysteine at residue 123 is
conspicuous by its absence in the majority of the NDV
isolates sequenced thus far (34). This is probably causally
related to the observation that the HN of NDV apparently
can exist in virions in either a disulfide-linked or a non-
disulfide-linked form, depending on the isolate, but does not
appear to be associated with any obvious difference in HN
function or antigenic structure (25, 27, 35). The presence of
cysteine at residue 123 correlates with the existence of
disulfide-linked dimeric HN in virions, implicating this cys-
* Corresponding author.
teine in intermolecular disulfide bonding between HN mono-
mers.
We initially characterized a panel of monoclonal antibod-
ies (MAbs) to antigenic sites 1, 2, 3, and 4 on the surface of
the HN glycoprotein of the AV isolate (13). However, many
MAbs produced by hybridomas isolated in subsequent fu-
sions were shown to map to sites which overlap two of the
original four sites and were named to reflect this, hence sites
12, 14, and 23 (12, 18). Since any one site overlaps at least
one other in competition antibody binding assays, our panel
of MAbs recognizes seven overlapping antigenic sites which
form a linked continuum (sites 4-14-1-12-2-23-3) on the
surface of the molecule. Functional inhibition studies re-
vealed that MAbs to three overlapping sites (12, 2, and 23)
inhibit the NA activity of the virus (12, 18). However,
analysis of variants, as well as other studies, indicated that
site 23 is probably closest to the actual NA site (19). MAbs
to these three sites, as well as those to sites 1 and 14, inhibit
hemagglutination (HA) (12, 14) and neutralize predominantly
by preventing viral attachment to chick cells (18). MAbs to
the two remaining sites (3 and 4) inhibit neither HA-attach-
ment nor NA but do inhibit the hemolytic activity of the
virus (14) and presumably neutralize at a postattachment
step.
We selected and characterized a variety of antigenic
variants which escape neutralization by an antibody to each
of the five sites on HN involved in viral attachment. Indi-
vidual amino acid substitutions were identified in the HN
proteins of these variants, making it possible to construct a
map of the neutralizing domains ofHN and providing insight
into its three-dimensional structure. These substitutions
clustered in three domains of the molecule. One domain
(amino acid residues 193 to 201) is part of a more extensive
region (171 to 205) previously implicated in the NA activity
of HN (19). The remaining two regions include (i) residues
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345 to 353 and (ii) residues 513 to 521 plus 494 and 569. The
former of these is a linear epitope which coincides with one
recognized in another NDV isolate by MAbs which also
inhibit HA (30).
Amino acid substitution in the attachment site on HN
could influence the receptor recognition properties of the
virus. Periodate treatment oxidizes the sialic acid moieties
on the surface of erythrocytes, rendering them resistant to
agglutination by viruses that recognize a sialic acid-contain-
ing receptor (37). Thus, substitution at amino acid residues
important to the recognition of cellular receptors might be
expected to alter the sensitivity of the virus-erythrocyte
interaction to periodate treatment. This was shown to be the
case for MAb-selected variants of influenza virus (38). We
show here that a substitution at position 193 of the HN of the
AV isolate renders the HA activity of the virus almost
threefold more resistant to periodate treatment of chicken
erythrocytes, indicating that this residue influences receptor
recognition.
MATERIALS AND METHODS
Virus. The Australia-Victoria (1932) (AV) isolate of NDV,
as well as variants and revertants derived from it, and the
Illinois-Great Lakes (GL) (1953) and Mexico-Texcoco (MT)
(1950) isolates were grown in the allantoic sacs of 10-day-old
embryonated hen eggs at 37°C from a stock of virus one egg
passage from cloning (2). After the death of the majority of
the embryos, allantoic fluid was harvested and virus was
purified as described previously (4, 41).
Cell culture. Primary and secondary chicken embryo cells
were prepared and maintained as described previously (2,
41). Confluent secondary cultures in 60-mm tissue culture
dishes were used for plaque assays.
Hybridomas and MAbs. The preparation of hybridomas
and the initial characterization of MAbs have been described
previously (12, 13, 18).
Selection of variants and isolation of revertants. Variants
were selected from cloned, passaged stocks of AV by escape
from neutralizing MAb, using rabbit anti-mouse immuno-
globulin (16). Each variant originated from a different pas-
saged stock, ensuring that they are independent isolates.
Variant 2a-1 is temperature sensitive, unable to form
plaques at the nonpermissive temperature of 41.8°C. Rever-
tants, no longer temperature sensitive for plaque formation,
were selected by plating the variant at the permissive tem-
perature (37°C), passaging virus from individual plaques in
eggs, and replating at the nonpermissive temperature. Only
one revertant from each stock was characterized.
ELISA and neutralization assay. MAb recognition of virus
was determined by assaying binding of hybridoma superna-
tants to intact virions in an enzyme-linked immunosorbent
assay (ELISA) (18). The ability of MAbs to block viral
infectivity was determined in a plaque neutralization assay
(15). Rabbit anti-mouse immunoglobulin treatment (16) was
used to verify binding by those MAbs which did not result in
neutralization.
Primer extension and dideoxy sequencing. The nucleotide
sequence of the entire HN gene of each variant and revertant
was determined by using 17-mer oligonucleotides comple-
mentary to that of the AV isolate (23) to prime dideoxynu-
cleotide chain termination-sequencing reactions. The prim-
ers, their purification, the primer extension reactions, and
the sequencing gel protocols have all been described previ-
ously (34), as has the preparation of virion RNA template
(19).
Western blots (immunoblots). Virion proteins (15 to 20,ug
per lane) (22) were resolved by electrophoresis in sodium
dodecyl sulfate (SDS)-10% polyacrylamide gels (21) in the
presence of 0.5 M 2-mercaptoethanol. After presoaking for 2
h in 25 mM Tris (pH 8.3)-192 mM glycine-50 mM NaCl-7 M
urea, proteins were transferred to Hybond-C Extra hybrid-
ization transfer membrane (0.45-,um pore size; Amersham
Corp., Arlington Heights, Ill.) for 16 to 18 h at 100 mA in 25
mM Tris (pH 8.3)-192 mM glycine-150 mM NaCl. Antibody
binding was detected by using the ECL Western Blotting
Detection system (Amersham) according to protocols pro-
vided by the company. Briefly, the filters were blocked for 1
h with 5% nonfat milk in phosphate-buffered saline (PBS)
containing 0.5% Tween 20 (PBS-T) before being cut into
strips and incubated for 1 h with ascites fluid preparations of
MAb at a concentration (14) of5 j±g/ml in PBS-T containing
0.5% milk. The strips were reacted for 1 h with a 1/10,000
dilution of horseradish peroxidase-conjugated goat anti-
mouse antibody (Kirkegaard & Perry Laboratories, Inc.,
Gaithersburg, Md.). All incubations were done on a rotary
shaker at room temperature, and the strips were washed
repeatedly with PBS-T between steps. After reaction for 1
min with the detection reagents provided by the company,
the strips were aligned in plastic wrap and exposed to Kodak
X-Omat film. After evaluation of a preliminary 30-s expo-
sure, longer exposures were made for strips when necessary.
Peptides. Peptides corresponding to amino acid residues
336 to 355 (NH2-IYKRYNDTCPDEQDYQIRMA-COOH),
337 to 351, and 341 to 355 were purchased from Multiple
Peptide Systems (San Diego, Calif.). Each was synthesized
with an N-terminal cysteine residue to facilitate cross-linking
to a carrier molecule for related experiments.
To determine MAb recognition of peptides, the ELISA
protocol (18) was modified such that 1 ,ug of peptide in PBS
was adsorbed overnight to each well of a microtiter plate,
blocked for 4 h with 0.25% nonfat milk in PBS, and incu-
bated overnight with serial twofold dilutions (starting con-
centration of 25 pug/ml) of MAb-containing ascites fluid. All
incubations were done in a moist chamber at room temper-
ature.
Periodate sensitivity test. To determine the effect of perio-
date treatment of erythrocytes on HA activity, we used a
modification of the method of Underwood (37). Erythrocytes
washed three times in PBS (10 mM Na2PO4, 3 mM KCl, 1.8
mM KH2PO4, 8.5% NaCl) containing 1% CaCl2 and MgCl2
were incubated for 30 min at room temperature with 0.1
volume of various concentrations (0.5 to 10 mM) of freshly
prepared sodium metaperiodate. A 0.1 volume of 40% glu-
cose was added to stop periodate oxidation before use of the
erythrocytes in an HA assay (19). The concentration of
periodate which decreased the HA activity of each virus by
4 HA units was determined.
Amino acid sequence homology and hydrophilicity profile.
The HN amino acid sequences of different paramyxoviruses
were aligned by using the DNASTAR Align program. The
published nucleotide sequence of the HN gene of the AV
isolate of NDV (23) predicted a protein of 570 amino acids
lacking the tyrosine at residue 184 of other isolates (20, 24).
We have since found that this tyrosine residue is, indeed,
present in the HN of the AV isolate (data not shown). This
eliminates the need to insert a space in the AV sequence at
this position to achieve maximum alignment (19). Previously
published variant amino acid substitutions, all of which are
carboxy terminal to residue 184 (19), have been renumbered
(plus 1) in this report.
Secondary structure was predicted by the method of Chou
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HEMAGGLUTININ-NEURAMINIDASE OF NEWCASTLE DISEASE VIRUS 5001
MONOCLONAL ANTIBODY
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FIG. 1. Reactivity of MAbs with variants and revertants. MAb
binding to virus was determined in an ELISA, and its ability to
neutralize viral infectivity was determined in a standard plaque
assay. Those for which antibody recognition of virus resulted in
detectable neutralization (persistent fraction of <80%) were then
tested for anti-immunoglobulin neutralization of antibody-sensitized
virus. The results were as follows: O, MAb does not recognize virus
(<20% of the binding to the wild-type virus) and does not neutralize
viral infectivity (persistent fraction of >80%); *, MAb neutralizes
virus to an extent similar to its neutralization of wild type (18); ED,
MAb recognizes virus in the ELISA (>50% relative to the wild type)
but neutralizes its infectivity ineffectively compared with the wild
type (>50% persistent fraction). Addition of anti-immunoglobulin,
however, results in complete neutralization.
and Fasman (3). The hydrophilicity profile of the HN protein
was generated from the published sequence (23) by using the
normalized consensus hydrophobicity scale of Eisenberg et
al. (6, 7), which is then used to predict the location of
antigenic sites.
RESULTS
Reactivity of anti-HN MAbs with antigenic variants. Com-
petitive antibody binding and additive neutralization assays
indicate that a panel of neutralizing MAbs recognize
epitopes within seven overlapping antigenic sites on HN (12,
13, 18). Since none of the anti-HN MAbs is sufficiently
neutralizing to allow the selection of variants in a simple
plaque neutralization assay, variant isolation required the
use of anti-immunoglobulin to neutralize MAb-sensitized
infectious virus (16).
Antigenic variants selected by escape from neutralization
with antibodies to each site were screened for binding and
neutralization by all MAbs to that site to map epitopes within
sites. Representative MAbs to heterologous sites were also
assayed to explore the possibility of an amino acid substitu-
tion in one site causing either a direct or a conformational
change in other sites (Fig. 1). There were three different
outcomes of the interaction of the neutralizing MAbs with
the variants: (i) failure to neutralize because the variant is
TABLE 1. Nucleotide and deduced amino acid substitutions in
variants and revertants
Variant Nucleotide Amino acid
substitution substitution
23a-3 668, T--C 193, Phe--Leu
23a-1 671, T- C 194, Ser--Pro
23f-1 672, C-*T 194, Ser--Phe
23a-2 693, A--C 201, His--Pro
la-3 1124, C--T 345, Pro-*Ser
la-i; lb-1; lb-2; lc-1 1125, C-*A 345, Pro-*Gln
la-2 1125, C- T 345, Pro-*Leu
14a7 1131, A--C 347, Glu-Ala
1569, A--G 493, Asp-*Gly
14b-1; 14d-l; 14f-1 1131, A--*G 347, Glu -Gly
14C-1; 14e41 1139, T--C 350, Tyr--His
14a-8; 14b-2 1149, G-*A 353, Arg-*Gln
12a-2 1571, G-*A 494, Asp-*Asn
2a-3 1628, C--A 513, Arg-*Ser
2a-2; 2b01 1629, G-*A 513, Arg--His
2a-la 1632, T-*C 514, Ile--Thr
2a-lRlla 1632, T--+C 514, Ile-*Thr
1652, A-*G 521, Arg--Gly
2a-lR6a 1632, T--C 514, Ile--Thr
1654, A--T 521, Arg--Ser
12e-i 1637, C--T 516, Arg-*Trp
12e-2 1638, G-*A 516, Arg--Gln
2b-2 1795, T-*A 569, Asp--Glu
a Each of these viruses also has a conservative nucleotide substitution at
position 1705 (T-+C).
not recognized by the MAb; (ii) neutralization similar to the
wild-type virus; and (iii) recognition, but ineffective neutral-
ization, of the variant by the MAb. In the last case, binding
was verified by ELISA or by enhanced neutralization medi-
ated by the addition of anti-immunoglobulin. Examples of
antibody binding to virions without neutralization include
several MAbs to site 14 and variants 14a-8 and 14C-1 (Fig. 1);
some of the site 23 MAbs and variants 23a-3 and 23f1 (19);
and the site 2 MAbs and variant 2a-1 (16).
Variant 2a-1 is temperature sensitive for plaque formation
(17). Two revertants of this variant, 2a-lR6 and 2a-1R11,
formed plaques at the nonpermissive temperature of 41.8°C.
These viruses also reverted for neutralization by the select-
ing antibody, 2a.
Two of the site 14 variants, 14C-1 (Fig. 1) and 14e-1 (data
not shown), were not recognized by antibodies to site 1.
Variant 2a-1 and its revertants were not recognized by MAbs
to site 12. These are the only examples among the panel of
variants of a substitution in one site resulting in escape from
neutralization by an MAb to a different site. However, it is
important to note that, for each of these variants, the
heterologous site topologically overlaps the homologous
site, suggesting that either the two sites share amino acid
residues or the substitutions in the variants induce a local
conformational change in HN. Therefore, it can be con-
cluded that the amino acid substitutions responsible for
escape from neutralization by the selecting MAbs do not
result in gross changes in the antigenic structure of HN.
MAbs which prevent virus attachment recognize epitopes in
three domains of HN. The complete nucleotide sequences of
the HN genes of variants selected with MAbs to sites 14, 1,
12, 2, and 23 were determined. The nucleotide and deduced
amino acid substitutions for each are listed in Table 1. With
one exception, each of the variants had a single nonconser-
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FIG. 2. Antigenic sites on the hydrophilicity profile of HN.
Hydrophilic regions of HN (peaks) are predicted by using the
normalized consensus (NCS) hydrophobicity scale of Eisenberg et
al. (6, 7), which predicts the localization of antigenic sites.
vative amino acid substitution in HN. The epitopes recog-
nized by antibodies to these sites could be localized to three
widely separated domains in the linear amino acid sequence
of the molecule.
(i) Site 23: residues 193 to 201. The amino acid substitu-
tions at residues 193, 194, 200, and 201 in variants selected
with MAbs to antigenic site 23 have been described previ-
ously in the course of identification of this domain as
important to the NA activity of HN (19).
(ii) Sites 1 and 14: residues 345 to 353. All six of the variants
selected with antibodies to site 1 had a substitution (glu-
tamine, leucine, or serine) for the proline residue at position
345 in the amino acid sequence of wild-type HN (Table 1).
Site 14 MAbs selected variants with substitutions at residue
347, 350, or 353. Variant 14a-7, selected with an MAb
isolated in a separate fusion, was the only one found to have
two amino acid substitutions, at residues 347 and 493.
(iii) Sites 12 and 2: residues 513 to 521 and 494 and 569.
Antibodies to site 2 selected variants with substitutions at
residue 513, 514, or 569. Revertants 2a-lR6 and 2a-1R11 are
pseudorevertants of 2a-1. Reversion of the temperature-
sensitive phenotype and neutralization by antibody are the
result of second-site substitutions, both at residue 521. Two
variants selected with site 12 antibodies had a substitution at
residue 516, and a third had a substitution at residue 494.
The three domains are all in hydrophilic regions of the
molecule. The localization of the three domains recognized
by MAbs that prevent attachment relative to the hydrophi-
licity profile of HN showed that the region of the molecule
recognized by site 14 and 1 MAbs (residues 345, 347, 350,
and 353) aligns with the broadest peak of hydrophilicity in
the linear amino acid sequence ofHN (Fig. 2). Similarly, the
remaining two domains also coincide with peaks of hydro-
philicity, but both are much sharper peaks centered around
residues 199 (site 23) and 516 (sites 12 and 2), respectively.
The hydrophilic regions around residues 258 and 279 coin-
cide with determinants recognized by MAbs which do not
block attachment (data not shown). None of the MAbs to the
HN glycoproteins of any of the paramyxoviruses selected a
variant with a substitution coinciding with the remaining
hydrophilic peak. This peak represents the 234-NRKSCS-
239 sequence that is completely conserved among the
Paramyxoviridae (26). Thus, we now have MAbs to most of
1 2 3 4 5 6 7 8 9 10
_NP
FIG. 3. Binding of MAbs to HN in Western blots. Virion pro-
teins were electrophoresed in SDS-10% polyacrylamide gels after
boiling and reduction. Separated proteins were then electrophoret-
ically transferred to nitrocellulose and cut into strips which were
reacted with MAbs as follows: lane 1, no MAb; lane 2, 12a; lane 3,
12,r~~~ ~ ~~~~~~' b; lane12'; lane 4, 12f; lane 5, 23a; lane 6, 23f; lane 7, 14a; lane 8, 14
9, 14f; lane 10, MAb to nucleocapsid (NP) were detected with the
enhanced chemiluminescence system, protein. Bound MAbs were
detected with the system, using an exposure time of 10 min for lanes
1 to 7 and 30 s for lanes 8 to 10.
the major regions of HN predicted to be exposed at the
surface of the molecule.
MAbs to site 14 recognize a continuous epitope. To deter-
mine whether any of the antibody-binding epitopes recog-
nized by these antibodies is a continuous determinant, we
assayed MAbs to each of the five sites for their ability to
recognize denatured HN. Figure 3 shows that site 14 MAbs
(except 14a) very efficiently recognized the non-disulfide-
linked monomeric form produced by boiling and reducing
HN, suggesting that they bind to a continuous epitope in the
sequence of HN. In contrast, MAbs to sites 12 and 23 could
not be shown to recognize boiled, reduced HN even after a
20-fold longer exposure (Fig. 3, lanes 2 to 6).
MAb 14a had a distinctly different pattern of reactivity
with the site 14 variants compared with the other site 14
MAbs (Fig. 1) and bound comparatively weakly in the
Western blots (Fig. 3, lane 7), also requiring a significantly
longer exposure for even weak detection. This suggests that
14a binds to an epitope that is slightly more dependent on
conformation than those recognized by the other site 14
MAbs. This may be related to the fact that one of its
variants, 14a-7' has a second substitution outside the domain
defining site 14.
We tried to further define site 14 through the use of
synthetic peptides corresponding to overlapping sequences
in this region of the molecule. Peptides corresponding to HN
residues 336 to 355, 337 to 351, and 341 to 355 were adsorbed
to microtiter ELISA plates and screened with antibodies to
site 14. Representative data for one site 14 MAb, 14f, are
shown in Fig. 4. All the site 14 MAbs, even 14a to a lesser
extent, recognized peptides corresponding to residues 336 to
355 and 341 to 355. The peptide corresponding to residues
337 to 351 was not recognized by the site 14 MAbs. In
addition, none of the peptides are recognized by MAbs
specific for any other HN antigenic site (data not shown).
These studies prove that site 14 is defined by the linear
amino acid sequence of HN residues 341 to 355 and that
residues 352 to 355 are required for antibody recognition.
The binding of site 14 MAbs to the peptides was of sufficient
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FIG. 4. Binding of MAbs to peptides. Twofold serial dilutions of
ascites fluid containing MAb 14f (starting concentration of 25 ,ug/ml)
were reacted in an ELISA with 1 ,ug of peptide dried onto a
microtiter plate. The peptides correspond to HN amino acid resi-
dues 336 to 355 (0), 337 to 351 (CI), and 341 to 355 (0).
affinity that pretreatment of the MAbs with the peptides they
recognized could protect the virus from neutralization by the
MAb (Fig. 5). Consistent with the ELISA data (Fig. 4), only
peptides corresponding to HN residues 336 to 355 and 341 to
355 were protective. Furthermore, neither protected the
virus from MAbs to other domains, e.g., site 1 (Fig. 5),
which topologically overlaps site 14.
Effect of periodate treatment of erythrocytes on HA by
variants. Each of the variants was assayed for its ability to
agglutinate chicken erythrocytes pretreated with increasing
concentrations of periodate to try to identify an amino acid
substitution(s) in HN that influences receptor recognition.
The results of the periodate sensitivity test are shown in Fig.
6. The concentration of periodate which decreases by 4 units
the HA activity of each variant is related to that which
similarly decreases the HA activity of the wild type, which is
set at unity. Variant 55D7-5, selected with an MAb to the F
glycoprotein, and a variant (3a-1), selected with an MAb to
HN that does not prevent viral attachment to the host cell
(18), served as controls and did not differ significantly from
the wild type in their periodate sensitivity.
The variant with the most significant alteration in period-
ate sensitivity was 23a-3, which had a single amino acid
1000
80-
Z
60-
Cl)
E 40 |
20-
Peptide: none A B C none A B C
MAb: 4t la
FIG. 5. Peptide inhibition of neutralization of viral infectivity by
antibody 14f. MAb 14f or la (100 ,ug/ml) was incubated with a
200-,ug/ml solution of peptides corresponding to HN amino residues
336 to 355 (A), 337 to 351 (B), or 341 to 355 (C). The bar graph shows
the percent persistent fraction surviving treatment by the MAb
without peptide and with each peptide.
RESISTANCE TO PERIODATE
FIG. 6. Effect of periodate treatment of erythrocytes on HA.
Erythrocytes to be used in HA assays were treated with periodate
(0.5 to 10 mM). "Resistance to periodate" shows the concentration
of periodate which decreased the HA activity of each virus by 4 HA
units relative to that which decreased the HA activity of the AV
isolate by 4 HA units.
substitution of leucine for the phenylalanine present at
residue 193 of the wild type. This substitution rendered
receptor recognition nearly threefold more resistant to peri-
odate treatment of erythrocytes than the wild-type HN,
indicating that the residue at this position strongly influences
receptor recognition.
Of five NDV isolates for which the sequence of the HN
gene is known, only AV has a phenylalanine residue at
position 193 (19). The majority of the others have leucine at
this position. Application of the periodate sensitivity test to
two other NDV isolates (MT and GL), which also have
leucine at position 193 (data not shown), indicated that they
have a level of resistance to periodate similar to that of
variant 23a-3 (Fig. 6). These findings suggest that the amino
acid residue at position 193 of HN influences receptor
recognition by NDV.
Several other variants, most notably 23a-1, lb-2, lc-1, 2a-3
and 12e-2, showed decreased resistance to periodate relative
to the wild type (Fig. 6). However, unlike 23a-3, no counter-
part in naturally occurring isolates was found, since each of
the amino acid residues substituted for in the above variants
is, as far as is known, conserved throughout the NDV
serotype (29).
DISCUSSION
Variants were selected with MAbs to five overlapping
antigenic sites on HN, each of which neutralizes viral
infectivity by preventing virion attachment to the host cell
(18). Escape from neutralizing antibody is attributable to
single nonconservative amino acid substitutions, making
possible the construction of a detailed neutralization map of
the attachment glycoprotein of the virus as summarized in
Fig. 7. The epitopes recognized by these MAbs are defined,
at least in part, by three widely separated domains in the
linear amino acid sequence of HN: residues 193 to 201 (site
23), 345 to 353 (sites 14 and 1), and 513 to 521 plus 494 and
569 (sites 12 and 2). Results obtained previously with com-
In 0p
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FIG. 7. Summary of location of amino acid substitutions in
variants selected with antibodies that prevent virion attachment to
cellular receptors. Positions of the amino acid substitutions in
variants (and revertants of 2a-1) as well as the proposed membrane-
spanning region (MSR) and potential glycosylation sites (shaded
boxes) are indicated.
petition antibody binding and additive neutralization assays
indicated that sites 14 and 1 partially overlap site 12 and that
sites 12 and 2 partially overlap site 23 (18). Thus, these three
regions are brought together at the surface of the molecule,
presumably near its receptor recognition site. This suggests
that the receptor-binding site on HN is probably also defined
by noncontiguous regions of the molecule brought together
in the native structure. These findings are consistent with
those from similar studies of the antigenic structure of the
attachment proteins of other paramyxoviruses such as Sen-
dai virus (36) and parainfluenza virus type 3 (5).
Regions of a virion attachment protein directly involved in
receptor recognition might be expected to show significant
sequence conservation among similar viruses. This would
certainly not be the case for antibody-binding epitopes,
which are inherently variable. The domain recognized by
MAbs to sites 14 and 1 and that recognized by MAbs to sites
12 and 2 are not well conserved in the members of the family
Paramyxoviridae (Fig. 8). It is possible that the relationship
between these antigenic sites and the receptor recognition
site in the HN ofNDV is similar to that in the hemagglutinin
of influenza virus. X-ray crystallographic studies of the
structure of the latter protein complexed with cell receptor
analogs show sialic acid bound in a pocket in the molecule
surrounded by antibody-binding sites (40). This gives the
virus a means to escape from neutralizing antibody, yet
retain its receptor recognition site.
With our findings concerning the site 1 and 14 MAbs and
those obtained with the Beaudette (30, 42) and D26 (10, 28)
isolates of NDV, three groups have now characterized
MAbs to epitopes localized to the most hydrophilic region of
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FIG. 8. Comparison of the deduced amino acid sequences of
residues 193 to 201, 345 to 353, and 513 to 521 for different
paramyxoviruses. Only amino acid (single-letter code) differences
are shown. Positions of variant substitutions are indicated by
arrowheads. The sequences are as follows: NDV AV (23), simian
virus 5 (SV5) (11), mumps virus (39), Sendai virus (1), and human
parainfluenza virus type 3 (hPF-3) (8).
the molecule in three different isolates of the virus. This
region is probably the immunodominant domain on HN.
Also, it is very likely that the epitope recognized by the site
14 MAbs corresponds to the Al epitope previously de-
scribed for the HN of the Beaudette isolate. MAbs to the
latter epitope also inhibit HA, bind in Western blots, and
select variants with substitutions at residues 347 and 349 (30,
42).
Unlike the other HN antigenic sites, that defined by HN
residues 193 to 201 (our site 23) showed a significant degree
of conservation among the paramyxoviruses (Fig. 8). Resi-
dues 195, 196, 198, and 199 were almost completely con-
served throughout the group. When one broadens the com-
parison (residues 171 to 206) to include residues on either
side of those known to contribute to the site 23 epitope, an
even more remarkable degree of conservation is revealed
(19).
Previous studies have revealed that this domain is also
directly involved in the NA activity of HN. Substitution at
residue 194 or 201 results in markedly altered NA (19) but, as
shown here, had no significant effect on sensitivity to peri-
odate treatment of erythrocytes (Fig. 6). On the other hand,
although substitution at HN residue 193 (variant 23a-3) has
no effect on NA activity (19), the relative periodate resis-
tance resulting from a substitution of leucine for the phen-
ylalanine at residue 193 of the HN of the AV isolate indicates
that this residue is probably directly involved in receptor
recognition. Thus, the site 23 domain includes residues
involved in both functions of the molecule, and substitution
within the domain differentially affects the attachment and
NA activities of the protein. This speaks to the long-debated
question of whether or not the attachment and NA sites on
HN are separate. Certainly, a great deal of evidence now
exists to support the notion that the two sites are separable
(reviewed in reference 19). However, the stretch of amino
acids from residues 193 to 201 is clearly involved in both
functions, so the two active sites probably overlap to a
certain extent. Confirmation of this awaits the solution of the
three-dimensional structure of the protein.
The isolation of variants which are not neutralized by the
selecting MAb but retain the ability to bind that antibody
adequately enough to ensure that the addition of anti-
immunoglobulin can effect neutralization has also been de-
scribed for antibodies to the hemagglutinin of influenza A
viruses (9). In fact, in both that system and NDV (17), the
antibodies which bind but do not neutralize nonetheless
inhibit the ability of the virus to agglutinate erythrocytes.
This phenomenon may be explained by considering the
prevention of attachment to cellular receptors by antibody as
a competition between HN for its receptor on cells and that
of the antibody for its epitope on HN. Inhibition of HA but
not attachment to chick cells may be explained by a differ-
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ence in affinity of the virus for receptors on chicken embryo
fibroblasts and erythrocytes. In wild-type HN, antibody
binds with sufficient avidity to compete with the binding of
HN to its cellular receptor on both erythrocytes and chick
cells. Variants which retain the ability to bind the selecting
antibody but escape neutralization by it may bind that
antibody with reduced avidity such that binding to the
receptor on chick cells, but not erythrocytes, is favored.
These variants are selected only by chance as they should be
indistinguishable from wild type in the anti-immunoglobulin
treatment required for variant selection.
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